Ovarian Cancer

Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade, advanced ovarian cancer.

Ryan M. Kahn, MD, MHS, FACOG, discusses the evolution of surgical techniques and practice-changing treatments in the ovarian cancer treatment paradigm.

Kathleen N. Moore, MD, MS, discusses the use of PARP inhibitors in patients with ovarian cancer.

The FDA accepted a NDA for relacorilant in platinum-resistant ovarian cancer based on data from ROSELLA and other phase 2 trials.

Alison Schram, MD, discusses the potential clinical utility of PKMYT1-targeted agents in gynecologic malignancies.

Ryan Matthew Kahn, MD, MHS, FACOG, discusses the importance of recognizing surgical limitations in the treatment of patients with advanced ovarian cancer.

Health Canada approved mirvetuximab soravtansine for folate receptor-alpha positive, platinum-resistant epithelial ovarian cancer.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.

Stenoparib receives FDA fast track designation for the treatment of patients with advanced ovarian cancer.

Ou Deng, PhD, discusses research aimed at clarifying the role of MSH6 in modulating sensitivity to PARP inhibitors in patients with BRCA-proficient HGSOC

Domenica Lorusso, MD, PhD, discusses the use of relacorilant plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Pamiparib with paclitaxel, carboplatin, and bevacizumab yields high complete cytoreduction rates, manageable safety in advanced ovarian cancer.

mRNA‑2416, alone or with durvalumab, was well tolerated and biologically active in advanced solid tumors and ovarian cancer.

The Geneva HRD test was predicitive for OS and PFS benefits with olaparib plus bevacizumab in advanced ovarian cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.

Alexander B. Olawaiye, MD, discusses key efficacy and safety findings from the ROSELLA trial and the future of relacorilant in platinum-resistant ovarian cancer.

The FDA has received an NDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Alexander B. Olawaiye, MD, discusses data with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer that led to the phase 3 ROSELLA trial.